# John Mulligan

> John Mulligan is the founder and CEO of Bonum Therapeutics, a Seattle biotech building antibody-regulated biologics that switch on only at their target. A serial entrepreneur with roughly 30 years across drug discovery and company formation, he has founded four companies in fields he often entered as a novice - including Good Therapeutics, whose PD-1-regulated IL-2 program Roche acquired in 2022 for $250M upfront. Bonum spun out of that deal with $93M in Series A funding to apply the same conditional-activation science across oncology, autoimmunity, metabolic disease, and pain. Mulligan holds a BS in biology from MIT and a PhD from Stanford, and was named a Top Industry Leader by the PharmaVoice 100 in 2023.

- **Role:** Founder and CEO at Bonum Therapeutics
- **Organizations:** Bonum Therapeutics, Good Therapeutics, Glycostasis, Blue Heron Biotech, Darwin Molecular, Nagoon Therapeutics
- **Nationality:** American
- **Education:** BS in Biology, Massachusetts Institute of Technology, PhD in Biology (doctoral and postdoctoral work), Stanford University
- **Known for:** Founded and led Good Therapeutics, whose conditionally active PD-1-regulated IL-2 program Roche acquired in 2022 for $250M upfront plus milestones, Raised a $93M Series A for Bonum Therapeutics in 2022, backed by Roche Venture Funds and new investor Vivo Capital, Founded Glycostasis, a glucose-responsive insulin company acquired by Eli Lilly

## Career timeline

- **1987** — Completes PhD at Stanford after roughly 12 years spanning doctoral and postdoctoral work
- **1990s** — Director of Genomics at Darwin Molecular; pioneers a genomic target-discovery approach that identifies an osteoporosis drug target
- **1999** — Founds Blue Heron Biotech, a gene-synthesis company, growing it from concept to commercial entity before its sale
- **2016** — Glycostasis, his glucose-responsive insulin company, is acquired by Eli Lilly
- **2022** — Roche acquires Good Therapeutics and its PD-1-regulated IL-2 program for $250M upfront plus milestones
- **2022** — Spins out Bonum Therapeutics and raises a $93M Series A in November led by existing investors plus Vivo Capital
- **2023** — Named a Top Industry Leader by the PharmaVoice 100

## Achievements

- Founded and led Good Therapeutics, whose conditionally active PD-1-regulated IL-2 program Roche acquired in 2022 for $250M upfront plus milestones
- Raised a $93M Series A for Bonum Therapeutics in 2022, backed by Roche Venture Funds and new investor Vivo Capital
- Founded Glycostasis, a glucose-responsive insulin company acquired by Eli Lilly
- Founded Blue Heron Biotech, a gene-synthesis company grown from concept to commercial exit
- Pioneered a genomic target-discovery approach at Darwin Molecular that identified an osteoporosis drug target
- Named a Top Industry Leader of 2023 by the PharmaVoice 100

## Latest updates

- **2025-03** — Bonum Therapeutics profiled on BiotechTV for its sensor-domain approach to lowering cytokine toxicity
- **2023-10** — Named a Top Industry Leader of 2023 by the PharmaVoice 100

## Links

- Website: https://bonumtx.com
- LinkedIn: http://www.linkedin.com/in/john-mulligan-ph-d-5aa5a37

---

Profile page: https://yespress.io/john-mulligan
Published by YesPress — https://yespress.io
Last updated: 2026-06-11